Oral GLP-1 Medications: Pills vs Injections Explained

The development of oral GLP-1 medications represents a major shift in treatment. For people who dislike injections, pills offer a compelling alternative - but how do they compare?

Currently Available: Rybelsus (Oral Semaglutide)

Rybelsus is the only FDA-approved oral GLP-1 receptor agonist. It contains semaglutide - the same active ingredient as Ozempic and Wegovy - in a daily tablet.

How Does an Oral Peptide Work?

Getting a large peptide like semaglutide absorbed through the gut was a significant pharmaceutical challenge. Novo Nordisk solved this with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer that:

• Protects semaglutide from stomach acid degradation
• Temporarily increases absorption through the stomach lining
• Enables enough drug to reach the bloodstream for therapeutic effect

This technology was described in a landmark 2019 paper in Science Translational Medicine (Buckley et al., 2019).

Rybelsus Dosing

Critical dosing rules:

• Take on an empty stomach first thing in the morning
• Swallow with no more than 4 ounces (120ml) of plain water
• Wait at least 30 minutes before eating, drinking, or taking other medications
• Do not crush, chew, or split the tablet

How Effective is Rybelsus?

The PIONEER clinical trial programme tested oral semaglutide across multiple studies:

• PIONEER 1: 14mg reduced HbA1c by 1.5% and body weight by 3.7kg vs placebo over 26 weeks
• PIONEER 6: Demonstrated cardiovascular safety

However, the current maximum dose of 14mg produces less weight loss than injectable semaglutide at 2.4mg (Wegovy). This is because oral bioavailability is only about 1% - most of the pill is not absorbed.

In Development: Higher-Dose Oral Semaglutide

Novo Nordisk is developing a 50mg oral semaglutide tablet specifically for weight loss. The OASIS 1 trial, published in The Lancet in 2023, showed remarkable results:

• 50mg oral semaglutide produced 15.1% weight loss over 68 weeks
• This is comparable to injectable Wegovy (14.9% in STEP 1)
• Nausea rates were similar to injectable semaglutide

(Knop et al., 2023, The Lancet)

This higher-dose oral formulation is expected to seek FDA approval and could dramatically change the treatment landscape by removing the injection barrier.

Also in Development: Orforglipron

Eli Lilly is developing orforglipron, an oral non-peptide GLP-1 receptor agonist. Unlike oral semaglutide (which is still a peptide requiring special formulation), orforglipron is a small molecule that can be taken more conventionally.

Phase 2 results published in the New England Journal of Medicine (2023) showed:

• Up to 14.7% weight loss over 36 weeks
• Can be taken without the fasting restrictions of Rybelsus
• Phase 3 trials (ATTAIN programme) are underway

(Wharton et al., 2023, NEJM)

Pills vs Injections: How Do They Compare?

Who Should Consider Oral GLP-1?

Oral GLP-1 may be a good fit if you:

• Have a strong aversion to needles
• Prefer taking a daily pill over a weekly injection
• Are managing type 2 diabetes (Rybelsus is currently approved for this)
• Want to try GLP-1 treatment with a potentially less intense side effect profile at lower doses

The Bottom Line

Oral GLP-1 medications are an exciting development. Current options (Rybelsus 14mg) provide moderate benefits primarily for diabetes, while next-generation oral formulations at higher doses are showing weight loss comparable to injections. Within the next few years, effective oral GLP-1 options for weight loss are likely to become available, making treatment accessible to many more people.

For more on the GLP-1 landscape, see our complete medication list or compare the best GLP-1 for weight loss.